Back to Authors

Nasseri, Yosef

https://orcid.org/0000-0002-9186-5717

Mayo Clinic

Surgery Group Los Angeles, Los Angeles, California, USA

Citations 3

Pre-Radioiodine Thyrotropin Thresholds During Withdrawal Preparation in Differentiated Thyroid Cancer after Total Thyroidectomy: A Systematic Review and Meta-Analysis
Rojas, Tatiana , Solís-Pazmiño, Paola , Figueroa, Luis , Ledesma, Tannya, Solis-Pazmino, Paola , Pazmino-Chavez, Camila, Naranjo, Eddy P. Lincango, Tite-Haro, María Belén , Alvarado-Mafla, Benjamin , Barrera-Flores, Francisco J., Nasseri, Yosef, Cohen, Jason, Toro-Tobon, David, Ponce, Oscar J., Figueroa, Luis A , Ledesma, Tannya M , Pilatuna, Eduardo A , Pazmino-Chavez, Camila N , Lincango Naranjo, Eddy P , Naranjo, Eddy P Lincango, Nasseri, Yosef , Toro-Tobón, David , Ponte, Oscar Ponce, Brito, Juan P.

Thyroid® | February 12, 2026 | Volume: 36 | Issue: 3 | Pages: 229-241

10.1177/10507256261423206 Get It

Background: Preparation for radioiodine (RAI) therapy in differentiated thyroid cancer (DTC) often requires thyroid hormone withdrawal (THW) to achieve thyrotropin (TSH) stimulation. Current guidelines recommend TSH ≥30 mIU/L, a target that prolongs hypothyroidism and worsens quality of life, yet rests on limited evidence. Objective: To evaluate the association between pre-RAI TSH levels and oncologic outcomes in adults with DTC prepared by THW. Methods: We conducted a systematic review and meta-analysis of studies comparing outcomes across pre-RAI TSH thresholds (<30 vs. ≥30, <60 vs. ≥60, and <90 vs. ≥90 mIU/L) in adults with DTC prepared by THW. Primary outcomes included disease-specific mortality, recurrence, and response to therapy. Searches in MEDLINE, Embase, Cochrane, and Scopus (inception to March 2025) identified eligible studies. Risk of bias was assessed using the CLARITY tool and certainty of evidence using GRADE. Pooled relative risks (RRs) were calculated using random-effects models. This systematic review was registered in PROSPERO (CRD42020158354). Results: This meta-analysis included eight retrospective cohort studies comprising a total of 4651 DTC patients, predominantly women (68.5%) with a mean age of 46 years. All patients underwent THW before RAI. Across all TSH thresholds examined (<30, <60, and <90 mIU/L), higher pre-RAI TSH levels were not associated with better treatment response, lower recurrence, or reduced mortality. Specifically, patients with higher pre-RAI TSH levels (≥30 mIU/L) did not have better oncologic outcomes compared with those with lower levels (<30 mIU/L). At 2- and 3-year follow-up, no significant differences were observed in excellent (pooled RR = 0.87; confidence interval [CI] 0.68–1.11) or indeterminate (RR = 1.28; CI 0.72–2.27) response rates. Similarly, recurrence rates did not differ (RR = 1.45; CI 0.83–2.55), and no study demonstrated a difference in disease-specific mortality across follow-up periods extending up to 10 years. The certainty of evidence for all outcomes was rated very low due to risk of bias, heterogeneity, and imprecision. Conclusions: The current evidence base is insufficient to support or refute the routine use of a specific TSH threshold before RAI administration. These findings question the recommendation to achieve TSH ≥30 mIU/L before RAI and highlight the need for trials to define the minimal effective level of TSH stimulation.
International Registry of thyroid cancer in Latin American (CaTaLiNA): epidemiology, clinical and follow-up study protocol in Latin American countries during the period 2023–2028
Solís-Pazmiño, Paola , Solis-Pazmino, Paola , Ledesma, Tannya, Alvarado, Brayner Alejandro Ramírez, Rojas, Tatiana, Pazmino, Camila , Tite, Belen, Figueroa, Luis, Hernández, Víctor, Salazar, Jorge, García, Cristhian, Rosero, Daniela, Ruilova, Lisbeth, Imaicela, Luis , Abad, Hamilton, Palacios, Antonio Lozano, Zanella, Virgílio Gonzales , Nasseri, Yosef , Cohen, Jason , Brito, Juan P. , Ponce-Ponte, Oscar J., Ponce, Oscar J. , Lincango, Eddy, Rojas, Tatiana , Brito, Juan P , Ponce, Oscar Josue , Pilatuna, Eduardo A , Ron, Mario , Alvarado, Benjamin, Figueroa, Luis, Lincango-Naranjo, Eddy , Rosero, Daniela, López‐Guerrero, José Antonio , Paz‐Ibarra, José , Gonzalez, Camilo, Palacios, Antonio, Soto-Becerra, Percy

BMJ Open | June 22, 2025 | Volume: 15 | Issue: 6 | Pages: e093471

10.1136/bmjopen-2024-093471 Get It

Introduction Differentiated thyroid cancer (DTC) is the most common endocrine malignancy, with a high 5-year survival rate of approximately 98%. Despite advances in diagnosis and treatment, up to 20% of patients experience recurrence, adversely affecting their quality of life. Predictive models have been developed to assess recurrence risk and guide clinical decision-making, but these models often face limitations such as retrospective design, lack of diversity in study populations and absence of external validation. The primary aim is to externally validate existing predictive models for DTC recurrence using prospective data from a diverse Latin American cohort. The secondary aim is to explore opportunities for model recalibration to improve their performance in our population. Methods and analysis The CaTaLiNA study is a multicentre prospective observational study conducted across 10 hospitals in five Latin American countries, including Ecuador, Peru, Uruguay and Mexico. Patients aged 18 years or older receiving treatment for DTC, such as the first thyroid surgery, active surveillance or radiofrequency ablation will be included. Recruitment will occur from November 2023 to June 2025, with follow-up extending until June 2028. Data collection will include baseline clinical, surgical and histological characteristics, treatment details and follow-up outcomes. Statistical analysis will follow the Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis guidelines, using imputation strategies for missing data and evaluating calibration and discrimination of the prediction models. Calibration measures include the ratio of expected and observed events, calibration slope and calibration plot, while discrimination will be assessed using the C-index and area under the receiver operating characteristic curve. Ethics and dissemination This study protocol was approved by Comité de Ética de Investigación en Seres Humanos de la Universidad San Francisco de Quito USFQ ‘CEISH-USFQ’ APO-010–2023-CEIHS-USFQ Oficio No. 161-2023-CA-23030M-CEISH-USFQ. Results will be disseminated via peer-reviewed publications.
The impact of surgeon speciality on surgical outcomes following colorectal resection for endometriosis
Nasseri, Yosef , Ma, Rachel , Fani, N. El , La, Kristina , Solís-Pazmiño, Paola , Xu, Runzhe , Wright, Kelly N. , Schneyer, Rebecca, Hamilton, Kacey M. , Barnajian, Moshe, Fani, Negin , Xu, Vincent , Meyer, Raanan , Siedhoff, Matthew T. , Schneyer, Rebecca J.

Colorectal Disease | February 14, 2025 | Volume: 27 | Issue: 2 | Pages: No page available

10.1111/codi.70028 Get It

AbstractAimAn estimated 5%–25% of women with endometriosis have colorectal involvement. Colorectal resection is the most suitable surgical management for cases with large bowel infiltration. However, this method is also associated with the highest rate of postoperative complications. Data focusing on surgeon speciality and surgical outcomes are currently limited. The aim of this work was to evaluate the surgical characteristics and short‐term postoperative outcomes following colorectal resection for endometriosis according to surgeon speciality.MethodUsing the National Surgical Quality Improvement Program (NSQIP) database, we included women who underwent colorectal resection for endometriosis between 2012 and 2020. Surgeries by general/colorectal surgeons were compared with those by gynaecological surgeons. The primary outcome was major complications according to the Clavien–Dindo classification.ResultsAmong 745 colorectal resections, 82.3% were performed by general/colorectal surgeons and 17.7% by gynaecologists. Racial and ethnic characteristics differed between groups, but other baseline characteristics were comparable. General/colorectal surgeons performed fewer minimally invasive surgeries (29.9% vs. 58.3%, p < 0.001). General/colorectal surgery cases had lower rates of any postoperative complications and minor complications (14.8% vs. 29.5%, p < 0.001; 10.1% vs. 23.5%, p < 0.001), while major complication rates were similar. Multivariable regression showed no association between major complications and surgical speciality. In a propensity score‐matched analysis, no significant differences were found between the two cohorts.ConclusionMost colorectal resections are performed by general/colorectal surgeons while a minimally invasive approach is more common among gynaecologists. There were no significant differences in outcomes between the two groups after adjusting for confounding variables. This suggests considering a multidisciplinary or dual surgery team approach to deep infiltrative endometriosis requiring bowel resection.